"I think the real effect the FDA advisory will have is to increase the likelihood that voluntary reporting of these events happens." Grupp added that multiple lines of previous treatment with chemotherapy could in theory be tied to later T cell malignancies. Dane Leone, an analyst at Raymond James who covers Bristol Myers Squibb, wrote in a note to clients how the FDA's reference to chimeric antigen receptor CAR-positive lymphoma could indicate "the drug product itself is transforming into T cell lymphoma." "If this is true, we are surprised that the U.S. FDA has not issued any clinical holds for the currently approved [autologous] CAR-T therapies listed within the press release," he wrote. The FDA recently announced it wants to hold an advisory committee as part of its review of Bristol Myers and 2seventy bio's application to move their CAR-T therapy Abecma into earlier treatment, although it isn't clear whether the meeting is related to the safety alert.